Evolving therapeutic approaches in late-onset genetic cholestasis

Real-world data show promise for IBAT inhibitor use in adults with late-onset PFIC and women with ICP.

Researchers evaluate the incidence of intrahepatic cholestasis of pregnancy recurrence and identify potential predictors.

Jeremy Nayagam highlights research on genetic testing in adults with unexplained cholestatic liver disease and hepatitis and explains why such testing is important in the diagnosis of these patients.

Clinical data suggest comparable IBAT inhibitor response for adults with hereditary BSEP deficiency as seen in pediatric trials.

A targeted next generation sequencing gene panel could offer a definitive diagnosis for some adults with unexplained cholestasis.

Intrahepatic cholestasis of pregnancy significantly increases the risk for developing hepatobiliary morbidity.

Researchers identify factors predicting improved native liver survival in adolescents with Alagille syndrome.

Study findings support early genetic testing for unexplained idiopathic chronic cholestasis and hepatitis of unknown origin.

Dr Marlyn Mayo and Dr Andreas Kremer share key insights on primary sclerosing cholangitis from AASLD The Liver Meeting 2025, and explore the latest in therapeutic developments and symptomatology.

Dr Silvia Vilarinho and Dr Deepak Joshi share the highlights from AASLD The Liver Meeting 2025, with an emphasis on late-onset genetic cholestasis, and offer quick insights into new data on the growing utility of genetic testing and expanding therapeutic implications.